搜尋結果
2024年5月7日 · 衛生福利部疾管署發言人曾淑慧今天在疫報記者會上指出，KP.2變異株為Omicron JN.1的子代變異株，具數個點位突變，目前占全球COVID-19病毒約11.4%，國內監測境外移入情況，占比也是大約10%，對整體疫情影響仍需持續評估。 曾淑慧說明，目前研究顯示KP.2的傳播力約JN.1的1.2倍，具成為主流變異株潛力，但致病力相對較低；且現有資料顯示，現有快篩與PCR等檢測工具仍可偵測到病毒，接種XBB.1.5疫苗也仍能產生辨識JN.1系列變異株之抗體；現有已核准藥物（PAXLOVID）仍持續有效。
2024年5月23日 · Google Scholar. Download PDF. The highly mutated SARS-CoV-2 Omicron subvariant BA.2.87.1, which emerged in South Africa in September 2023 (1, 2), has garnered global interest due to its unique constellation of many mutations in...
2024年5月22日 · 目前新研究顯示，BA.2引起的確診可能超過Omicron原本的毒株，但不太可能增加重症住院或死亡人數。 加拿大薩斯喀徹溫大學（University of Saskatchewan）疫苗和傳染病組織 (VIDO) 的病毒學家雷斯穆森（Angela Rasmussen）表示，最初Omicron原株BA.1引發的疫情達到高峰時，很多人都去接種疫苗和加強劑，現在這些人有相對高的抗體可以防止感染BA.2。
2024年5月20日 · The JN.1 variant (BA.2.86.1.1), arising from BA.2.86.1 with the S:L455S substitution, showed increased fitness and outcompeted the previous dominant XBB lineage by the beginning of 2024.1 JN.1 subsequently diversified, leading to the emergence of descendants with spike (S) protein substitutions such as S:R346T and S:F456L. Particularly, the KP.2 (JN.1.11.1.2) variant, a descendant of JN.1 ...
2024年5月15日 · Other risk factors had variable relationship with risk of infection, with changes seeming to especially correlate with the emergence of Omicron BA.2 dominance. These variable factors were mask-wearing habits, history of foreign travel, household size, working status (retired or not) and contact with children or persons age over 70.
1 天前 · Among the sample pairs, four were from Alpha infections, four from Delta, 29 from Omicron (14 from BA.1 and 15 from BA.2), and 23 from other SARS-CoV-2 variants (Table 1). The samples were predominantly collected from young adults, who all had mild symptoms at the time of testing with a mean age of 30 years (range: 17–66 years) ( Table 1 ; Supplementary Table S1 ).
3 天前 · In this significant study, 20.2% of HCWs achieved seroprotection against Omicron subvariants BA.1, BA.4, and BA.5. Their immunity against Omicron subvariants was further reinforced through recommended vaccinations and the development of natural immunity from SARS-CoV-2 exposure, collectively enhancing their protection against Omicron.
